Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (25465)	2/3/2000 11:51:00 AM
From: Bidder	Read Replies (1) \| Respond to of 52051

SW, TNRG up to .80 yesterday!! Down to .40 today! bought in at .47!! Tuesday February 1, 3:03 pm Eastern Time Company Press Release SOURCE: Tianrong Building Material Holdings, Ltd. TNRG Receives FDA Approval for Electrocardiogram Monitor NEW YORK, Feb. 1 /PRNewswire/ -- Tianrong Building Material Holdings, Ltd. (OTC Bulletin Board: TNRG - news) announced today that it has received approval from the Food & Drug Administration (''FDA'') for its personal computer based electrocardiogram monitor known as ''The Tracker.'' This battery powered PC-ECG monitor will provide a reliable means to acquire, display, store and print patients' ECG signals through a personal computer. The ECG signals can also be transferred to remote computers by floppy disk or E-mail. It is suited to store a record of a patient's infrequent and elusive ECG events and for general monitoring purposes. The collected data can be used to aid physicians in their diagnosis and treatment of cardiovascular diseases. The FDA has informed TNRG that the official notification of approval will be available on the FDA's website (http://www.fda.gov) by the middle of February. Until then, TNRG shareholders and other interested parties can view the approval letter from the FDA by visiting (http://www.tnrg.com/fda-approval.htm ). According to the Department of Health and Human Services, cardiovascular diseases (CVD) are the leading cause of death and illness in the United States. Fifty-eight million Americans suffer from one or more types of CVD. The estimated cost of CVD in 1998 in the U.S. alone was $274 billion. James Tilton, President of TNRG stated, ''I am sure that all of our shareholders join me in the immense feeling of pride and gratitude towards all of the management and staff of our Medical Division.'' Tianrong is a business development company that intends to engage in the acquisition of businesses across several sectors and, through the application of its management expertise, to enhance shareholder value. For further information contact investor relations at 800-324-3464 or visit tnrg.com